• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Meds for Alcohol Use Disorders

Meds for Alcohol Use Disorders

January 18, 2022
Mikveh Warshaw, NP.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Mikveh Warshaw, NP. Ms. Warshaw has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Heikkinen M et al, Addiction 2021;116(8):1990–1998

STUDY TYPE: Cohort study

In the US, only 9% of patients diagnosed with alcohol use disorder (AUD) are prescribed AUD medication (Kranzler HR and Soyka M, JAMA 2018;320(8):815–824). A Swedish study provides evidence that further illuminates the potential harms from this lack of treatment. The study compares the real-world impact of four medications, three of which—disulfiram, naltrexone, and acamprosate—are FDA approved for AUD.

Researchers used national databases in Sweden to identify 125,556 people (62.5% men) ages 16–64 with a diagnosis of AUD and followed them prospectively for 10 years. They excluded individuals with schizophrenia or bipolar disorder. The researchers recorded whether participants picked up prescriptions for naltrexone, disulfiram, acamprosate, or nalmefene (an opioid antagonist similar to naltrexone that is not available in the US). The primary outcome researchers tracked was hospitalization due to AUD.

Data suggested that naltrexone reduced rates of hospitalization, both as a monotherapy and when combined with disulfiram or acamprosate. For hospitalizations due to alcohol-related causes, naltrexone monotherapy decreased rates by 11%, naltrexone + acamprosate decreased rates by 26%, and naltrexone + disulfiram decreased rates by 24%. The results were nearly identical for all-cause hospitalization.

At first glance, it may seem that naltrexone in combination with another medication is the best option. But the authors point out that even though combinations outperformed naltrexone monotherapy, patients who receive combination medication may also be more likely to be receiving specialist case, and that the lower hospitalization rates might result from the specialist care rather than the medications themselves.

Surprisingly, acamprosate was associated with increased risk of hospitalization. The authors speculate that acamprosate’s poor efficacy may partially be explained by the fact that it requires dosing three times daily, and as a result we can surmise that adherence was poorer in the acamprosate arm than for other medications. But it’s not clear why this would be associated with worse outcomes than no medication at all. Disulfiram and nalmefene monotherapy were not associated with significantly different rates of hospitalization.

Finally, researchers found that benzodiazepines were associated with both an 18% increased hospitalization rate due to AUD and an 11% higher mortality rate. While this result is not unexpected, it does emphasize the dangers of prescribing benzos to patients who are actively drinking or diagnosed with AUD.

CATR’S Take
While this study does not investigate the nuances of treatment planning, it does support that naltrexone, both alone and in combination with disulfiram or acamprosate, is one of the most promising medications for AUD. It also emphasizes that we should exercise great caution when prescribing benzodiazepines for these patients.

__________

The Carlat CME Institute is accredited by the ACCME to provide continuing medical education for physicians. Carlat CME Institute maintains responsibility for this program and its content. Carlat CME Institute designates this enduring material educational activity for a maximum of one quarter (.25) AMA PRA Category 1 CreditsTM. Physicians or psychologists should claim credit commensurate only with the extent of their participation in the activity.

Addiction Treatment
KEYWORDS alcohol-use-disorder naltrexone observational-study psychopharmacology
    Mikveh Warshaw, NP.

    Taking a Sexual History With Children and Teens

    More from this author
    www.thecarlatreport.com
    Issue Date: January 18, 2022
    SUBSCRIBE NOW
    Table Of Contents
    A Primer on Vaping: 15 Years On
    Using Smoking Cessation Medications in Patients With Mental Illness
    Antipsychotics for Methamphetamine Psychosis
    Meds for Alcohol Use Disorders
    CME Post-Test - Smoking Cessation, CATR, January/February 2022
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.